MPLTMapLight Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−57% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 22). Price is −57% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 3.8% since the previous count, up from 4.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MPLT is trading
- vs 200-day average
- −57%
vs 200-day average · a clear downtrend
- RSI (14)
- 22
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 78%
Below its 52-week high
Details›
- Last close2026-10-09
- $8.83
- 1 monthS&P 500 +2.7%
- −36%
- vs 50-day average$11.64
- −24%
- 52-week high
- $39.24
- 52-week low
- $8.83
- Annualised volatility
- 117%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$7.6M
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry